BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: du Toit N, van Coller R, Anderson DG, Carr J, Bardien S. Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson’s disease. Neurogenetics 2019;20:215-8. [DOI: 10.1007/s10048-019-00588-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Müller-Nedebock AC, Meldau S, Lombard C, Abrahams S, van der Westhuizen FH, Bardien S. Increased blood-derived mitochondrial DNA copy number in African ancestry individuals with Parkinson's disease. Parkinsonism Relat Disord 2022;101:1-5. [PMID: 35728366 DOI: 10.1016/j.parkreldis.2022.06.003] [Reference Citation Analysis]
2 Simpson C, Vinikoor-Imler L, Nassan FL, Shirvan J, Lally C, Dam T, Maserejian N. Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review. Parkinsonism Relat Disord 2022;98:103-13. [PMID: 35654702 DOI: 10.1016/j.parkreldis.2022.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Müller-Nedebock AC, Komolafe MA, Fawale MB, Carr JA, van der Westhuizen FH, Ross OA, Bardien S. Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa. Mov Disord 2021. [PMID: 34228376 DOI: 10.1002/mds.28710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Abrahams S, Miller HC, Lombard C, van der Westhuizen FH, Bardien S. Curcumin pre-treatment may protect against mitochondrial damage in LRRK2-mutant Parkinson's disease and healthy control fibroblasts. Biochem Biophys Rep 2021;27:101035. [PMID: 34189277 DOI: 10.1016/j.bbrep.2021.101035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
5 Rizig M, Ojo OO, Athanasiou-Fragkouli A, Agabi OP, Oshinaike OO, Houlden H, Okubadejo NU. Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson's disease. Neurobiol Aging 2021;99:101.e15-9. [PMID: 33158606 DOI: 10.1016/j.neurobiolaging.2020.09.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rizig M, Ojo OO, Athanasiou-fragkouli A, Agabi OP, Oshinaike OO, Houlden H, Okubadejo NU. Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson’s disease.. [DOI: 10.1101/2020.06.30.179739] [Reference Citation Analysis]
7 Dekker MCJ, Coulibaly T, Bardien S, Ross OA, Carr J, Komolafe M. Parkinson's Disease Research on the African Continent: Obstacles and Opportunities. Front Neurol 2020;11:512. [PMID: 32636796 DOI: 10.3389/fneur.2020.00512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]